{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:39:48Z","timestamp":1766407188116},"reference-count":8,"publisher":"Academy of Managed Care Pharmacy","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.18553\/jmcp.2020.26.6.782","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T17:49:35Z","timestamp":1590688175000},"page":"782-785","source":"Crossref","is-referenced-by-count":4,"title":["The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease"],"prefix":"10.18553","volume":"26","author":[{"given":"Patricia G.","family":"Synnott","sequence":"first","affiliation":[{"name":"Institute for Clinical and Economic Review, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Brett","family":"McQueen","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Ollendorf","sequence":"additional","affiliation":[{"name":"Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven D.","family":"Pearson","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Economic Review, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7818","reference":[{"issue":"4","key":"B1","doi-asserted-by":"crossref","first-page":"e002470","DOI":"10.1161\/CIRCGEN.119.002470","volume":"12","author":"Patel R","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709118"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500857"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.07.768"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060989"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.03.025"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812792"},{"key":"B8","unstructured":"Ollendorf D, McQueen R, Campbell J, et al. Additive therapies for cardiovascular disease: effectiveness and value. Institute for Clinical and Economic Review. October 17, 2019. Available at: http:\/\/icer-review.org\/material\/cvd-final-evidence-report\/. Accessed April 30, 2020."}],"container-title":["Journal of Managed Care & Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T12:43:46Z","timestamp":1666701826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2020.26.6.782"}},"subtitle":["A Summary from the Institute for Clinical and Economic Review\u2019s Midwest Comparative Effectiveness Public Advisory Council"],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.18553\/jmcp.2020.26.6.782"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2020.26.6.782","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}